Yescarta data bolster flagging CAR-T profile

Gilead Sciences (Nasdaq: GILD) has revealed promising five-year data from its Phase II ZUMA-5 trial of Yescarta (axicabtagene ciloleucel), at the American Society of Hematology meeting.

The study examines long-term survival in people with relapsed or refractory non-Hodgkin lymphomas. Data show an overall response rate of 90%, with 75% of patients achieving complete remission.

Lead investigator Sattva Neelapu said: “Relapsed or refractory non-Hodgkin lymphomas are generally considered incurable, with most patients ultimately relapsing,” adding: “These impressive results demonstrate the durable clinical benefit and manageable long-term safety profile of axi-cel and give us hope it may have a curative effect.”